title: Immunomodulatory activity of analog of muramyl dipeptide and their use as adjunct to chemotherapy of Leishmania donovani in hamster.
abstract: In search of a potent immunomodulator to be used as an immunoprophylactic agent and as adjunct to chemotherapy against Leishmania infection, two analogs of muramyl dipeptide, viz. N.Ac-norMur-MeVal-D-isoGln (86/448) and N.AcMur-Acc-D-isoGln (89/729) were evaluated for desired activity. Effect of these peptides on cell mediated and humoral immunity was studied by immunizing the peptide treated mouse with sheep red blood cells (SRBC) and determining HA-titer, plaque forming cells assay and delayed type of hypersensitivity (DTH) response after 4-5 days. Both the peptides stimulated cell mediated immunity (CMI), humoral response as well as macrophage function in terms of super oxide anion (O2-) and nitric oxide (NO) generation. Mitogen induced lymphocyte proliferation and production of IL-2 and INF-gamma increased while that of IL-4 and IL-10 decreased by both the peptides showing a typical Th1 type response. After establishing the immunostimulatory activity, these peptides were evaluated for immunoprophylactic efficacy as well as for use as adjunct to chemotherapy with stibanate (SSG) against Leishmania donovani infection in golden hamster. These peptides were found quite effective in both the modes. In adjunct use the treatment may require lower dose of SSG and thereby reduce the chances of drug toxicity.
authors.affiliation: Division Biochemistry, Central Drug Research Institute, Lucknow-226001, India. anjup4@rediffmail.com
authors.forename: A
authors.initials: A
authors.lastname: Puri
authors.forename: R
authors.initials: R
authors.lastname: Sahai
authors.forename: W
authors.initials: W
authors.lastname: Haq
authors.forename: A
authors.initials: A
authors.lastname: Zaidi
authors.forename: P Y
authors.initials: PY
authors.lastname: Guru
authors.forename: L M
authors.initials: LM
authors.lastname: Tripathi
authors.forename: V M L
authors.initials: VM
authors.lastname: Srivastava
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D016516:CD4-CD8 Ratio; D006224:Cricetinae; D016207:Cytokines / Q000096:biosynthesis; D004359:Drug Therapy, Combination; D004912:Erythrocytes / Q000276:immunology; D007893:Leishmania donovani; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000469:parasitology / Q000517:prevention & control; D008213:Lymphocyte Activation; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009569:Nitric Oxide / Q000378:metabolism; D012756:Sheep / Q000276:immunology; D013154:Spleen / Q000469:parasitology; D013481:Superoxides / Q000378:metabolism
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D013481:Superoxides; D009569:Nitric Oxide; D000119:Acetylmuramyl-Alanyl-Isoglutamine